Advertisement

Seminars in Immunopathology

, Volume 38, Issue 4, pp 409–423 | Cite as

The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation

  • Aleksander M. Grabiec
  • Tracy Hussell
Open Access
Review

Abstract

Acute and chronic inflammatory responses in the lung are associated with the accumulation of large quantities of immune and structural cells undergoing apoptosis, which need to be engulfed by phagocytes in a process called ‘efferocytosis’. Apoptotic cell recognition and removal from the lung is mediated predominantly by airway macrophages, though immature dendritic cells and non-professional phagocytes, such as epithelial cells and mesenchymal cells, can also display this function. Efficient clearance of apoptotic cells from the airways is essential for successful resolution of inflammation and the return to lung homeostasis. Disruption of this process leads to secondary necrosis of accumulating apoptotic cells, release of necrotic cell debris and subsequent uncontrolled inflammatory activation of the innate immune system by the released ‘damage associated molecular patterns’ (DAMPS). To control the duration of the immune response and prevent autoimmune reactions, anti-inflammatory signalling cascades are initiated in the phagocyte upon apoptotic cell uptake, mediated by a range of receptors that recognise specific phospholipids or proteins externalised on, or secreted by, the apoptotic cell. However, prolonged activation of apoptotic cell recognition receptors, such as the family of receptor tyrosine kinases Tyro3, Axl and MerTK (TAM), may delay or prevent inflammatory responses to subsequent infections. In this review, we will discuss recent advances in our understanding of the mechanism controlling apoptotic cell recognition and removal from the lung in homeostasis and during inflammation, the contribution of defective efferocytosis to chronic inflammatory lung diseases, such as chronic obstructive pulmonary disease, asthma and cystic fibrosis, and implications of the signals triggered by apoptotic cells in the susceptibility to pulmonary microbial infections.

Keywords

Efferocytosis Phosphatidylserine Apoptotic cell clearance Lung Airway macrophage Inflammation 

Cellular turnover occurs as part of the normal homeostatic process and is vital for the contraction of cells recruited during an inflammatory response [1]. As with most biological processes, it is becoming apparent that turnover of cells is regulated in a tissue-specific manner and this specificity is primarily driven by locally produced factors. For example, the unique microenvironment of the airspaces drives a distinct expression pattern of apoptotic cell recognition receptors on airway macrophages compared to tissue-resident macrophages from other anatomical locations [2]. In the airways, cell turnover is primarily mediated by induction of apoptosis followed by engulfment of apoptotic cells by phagocytes, called ‘efferocytosis’. The term ‘efferocytosis’ was coined to separate engulfment of apoptotic cells from other forms of phagocytosis and derived from the Latin word ‘effere’ that translates as ‘take to the grave’. While phagocytosis of pathogens requires initiation of an inflammatory response, removal of self-cells that undergo apoptosis is a tolerogenic process that prevents excessive inflammation and/or autoimmunity caused by the release of ‘damage associated molecular patterns’ (DAMPS) from apoptotic cells that are not cleared in a timely manner and undergo secondary necrosis. To achieve this distinction, macrophages and other phagocytes utilise different sets of receptors to recognise microbial particles and cells undergoing apoptosis, activation of which subsequently leads to distinct cell activation programmes. Whereas phagocytosis of pathogens triggers conserved pro-inflammatory signalling pathways, engulfment of apoptotic cells by phagocytes may promote the wound repair process, the production of factors to curtail inflammation or the secretion of growth factors to shape a developing tissue. Efferocytosis therefore leads to different consequences and is a burgeoning focus of research, driven by the discovery of ever more apoptotic cell recognition receptors and, importantly, pathogens that use the apoptotic cell clearance process to facilitate their entry into host cells and/or subvert anti-pathogen immunity.

Mechanisms of efferocytosis

The distinction between apoptotic and healthy cells is mediated primarily by the release of ‘find-me’ signals from apoptotic cells that include ATP and UTP [3], fractalkine (CX3CL1) [4], lysophosphatidylcholine [5] and sphingosine-1-phosphate [6]. In addition to recruitment, such soluble signals may also enhance the engulfment capacity of the responding cell. For example, apoptotic cell production of fractalkine induces milk fat globule-epidermal growth factor 8 (MFG-E8) expression in phagocytes that enhances apoptotic cell clearance [7].

Apoptotic cells expose a variety of molecules on their cell surface that can be recognised by receptors on phagocytic cells. The precise composition of such ‘eat-me’ signals likely depends on whether apoptosis is occurring under homeostatic conditions or during inflammation and is tissue- and cell type-specific [1, 8]. One of the best studied ‘eat-me’ signals is phosphatidylserine (PtdSer) that in living cells is localised to the inner leaflet of the plasma membrane and is externalised upon induction of apoptosis [9]. Overexpression of PtdSer enhances apoptotic cell engulfment, whereas PtdSer blockade suppresses this process, leading to autoimmunity [10, 11]. Irreversible externalisation occurs when caspases inactivate flippase (ATP11C) that in healthy cells continually flips PtdSer in the plasma membrane [12]. At the same time, caspase-dependent activation of scramblases (such as Xkr8), which non-specifically and bi-directionally scramble phospholipids in the plasma membrane, is also required for PtdSer exposure on apoptotic cells [13]. PtdSer is transiently exposed on the surface of living cells that resist efferocytosis, suggesting that this signal alone may not be enough, or that prolonged interaction of PtdSer receptors on phagocytes is required [14]. Oxidised low-density lipoprotein, calreticulin, annexin A1, ICAM3, C1q and thrombospondin-1 (TSP1) are also implicated in efferocytosis [1]. Furthermore, healthy cells prevent engulfment by expressing CD47 and CD31 [15, 16] or by ligating CD300a that impedes macrophage function [17]. A balance of efferocytosis-inducing and inhibitory signals may therefore determine apoptotic cell clearance.

PtdSer and other ‘eat-me’ signals exposed on apoptotic cells bind a plethora of receptors on phagocytic cells, a number of which have been identified in the lung (Table 1). Externalised PtdSer is recognised directly by triggering receptor expressed by myeloid cells-2 (TREM2) [30], CD300 [31], receptor for advanced glycation end products (RAGE) [32], stabilin-2 [33], brain-specific angiogenesis inhibitor-1 (BAI1) [34] and the family of T cell/transmembrane, immunoglobulin, and mucin (TIM) receptors, which includes TIM-1, 3 and 4 [35, 36]. Other engulfment receptors require bridging molecules to link them to externalised PtdSer. For example, integrin αvβ3 or αvβ5 requires MFG-E8, while Tyro3, Axl and MerTK that form the TAM receptor tyrosine kinase family [37] require the bridging molecules Protein S or growth arrest specific 6 (Gas6) [38]. The N-terminal Gla domains of Protein S and Gas6 bridge TAM receptors to PtdSer on the surface of apoptotic cells [39], whereas the C-terminal sex hormone-binding globulin-like domains bind and activate the TAM receptor [40]. There are also a number of receptors that recognise other externalised ligands including scavenger receptor class F, member 1 (SCARF1) and LDL receptor-related protein-1 (LRP-1, also known as CD91) that recognise C1q and calreticulin, respectively, CD36 together with integrin αvβ3 or αvβ5 that recognises TSP-1, CD14 that binds a modified form of the intracellular adhesion molecule ICAM3, and lectin receptors that recognise altered sugars [1].
Table 1

‘Eat-me’ signals exposed on apoptotic cells and their recognition receptors expressed on phagocytes

‘Eat-me’ signal

Receptor

Receptor expression on airway macrophages

PtdSer

TIM family (TIM-1, 3 and 4)

Not studied

TAM family (Tyro3, Axl, MerTK) through Gas6 and Protein S

High Axl and MerTK expression in mice, only MerTK studied and confirmed in humans [2, 18]

BAI1

Not studied

RAGE

Confirmed in mice [19] and humans [20]

Stabilin-2

Not studied

Integrin αvβ3 or αvβ5 through MFG-E8

Low αvβ3 expression in humans [21, 22]

TREM2

Confirmed in mice [23] and humans [24]

TSP-1

CD36 (in complex with integrin αvβ3 or αvβ5)

Confirmed in humans [21, 25]

ICAM3

CD14

Low expression in mice [26] and humans [27]

Altered sugars

Lectin receptors

Mannose receptor confirmed in mice [26] and humans [28]

Calreticulin

LRP-1/CD91

Confirmed in mice [29] and humans [22, 29]

C1q

SCARF1

Not studied

BAI1 brain-specific angiogenesis inhibitor-1, ICAM3 intracellular adhesion molecule-3, LRP-1 LDL receptor-related protein-1, MFG-E8 milk fat globule-epidermal growth factor 8, PtdSer phosphatidylserine, RAGE receptor for advanced glycation end products, TSP-1 thrombospondin-1, SCARF1 scavenger receptor class F, member 1, TIM T cell/transmembrane, immunoglobulin, and mucin, TREM2 triggering receptor expressed on myeloid cells-2

The logic behind possessing so many receptors that can recognise apoptotic cells is not entirely clear. Some, such as TIM-4, act as tethering receptors without any signalling consequences [41], similar to CD14 [42]. Different receptors may also act at different stages of efferocytosis [43] or may preferentially clear cells in different locations. For example, TREM2 and TREM2-L form a receptor-ligand pair connecting microglia with apoptotic neurons, directing removal of damaged cells to allow repair [44]. It is also likely that an alternate outcome is required upon efferocytosis that requires linkage to different signalling components [31]. With regard to the TAM receptors, MerTK is ubiquitously expressed on macrophages and even used as a defining marker for them. Airway macrophages, however, unlike most other macrophages, constitutively express Axl, possibly due to the local environment that is rich in granulocyte-macrophage colony-stimulating factor (GM- CSF) [2]. Importantly, receptors that recognise apoptotic cells can also play a dual function: inducing the cytoskeletal rearrangements necessary to ingest the apoptotic cell and also transmitting an instructive signal [45]. It is interesting to note that individual TAM receptor family members use different molecules to bridge them to PtdSer externalised on apoptotic cells: MerTK and Tyro3 are activated by both Gas6 and Protein S, whereas the sole ligand for Axl is Gas6 [46, 47]. In the case of MerTK and Tyro3, it is therefore possible that specific signals triggered by receptor ligation might differ depending on the bridging molecule, though this possibility remains to be verified experimentally. Finally, further selectivity of response is afforded by co-operation of multiple receptors such as Axl and LRP-1 on dendritic cells where Axl tethers the apoptotic cell to dendritic cells, but LRP-1 is required to trigger internalisation [48].

Impact of efferocytosis on cell function

The receptors that mediate efferocytosis often have anti-inflammatory signalling consequences that can change the phenotype and function of the ingesting cell. For example, engagement and activation of TAM receptors inhibits signalling pathways triggered by cytokines and toll-like receptor ligands through induction of suppressor of cytokine signalling-1 and 3 (SOCS-1 and 3) [49, 50] (see Fig. 1a, b). The impact of apoptotic cell clearance on cell function depends on the cell type mediating efferocytosis, which in turn depends on tissue location. In the lung, efferocytosis is mediated predominantly by macrophages and airway epithelial cells, with most consequences studied in the former. In macrophages, efferocytosis increases the secretion of the anti-inflammatory cytokines, transforming growth factor-β (TGF-β) and interleukin (IL)-10 [51, 52], while inhibiting secretion of proinflammatory mediators such as TNF-α, IL-1, IL-8 and leukotriene C4 [53, 54]. IL-10 production by macrophages upon apoptotic cell contact is, in part, dependent upon the scavenger receptor CD36 [51] and TSP-1, which links macrophages to apoptotic cells in cooperation with integrin αvβ3 [55]. Efferocytosis also upregulates prostaglandin E2 (PGE2) and impairs FcR-mediated phagocytosis [54, 56], and intratracheal instillation of apoptotic cells enhances the resolution of LPS-induced acute pulmonary inflammation [57]. This change in function from pro-inflammatory to pro-resolution can be observed as a phenotypic switch from an M1- to an M2-like macrophage phenotype and includes the induction of peroxisome proliferator-activated receptor-γ (PPARγ) [58]. However, this is likely to be context-, cell-type- and tissue-dependent. For example, nitric oxide, but not IL-10, TGF-β or PGE2, mediates the immunosuppressive effects induced by apoptotic cell efferocytosis in dendritic cells [59]. It is also interesting to note that efferocytosis by dendritic cells appears to be subset-specific. Only CD103+ murine lung dendritic cells capture and present apoptotic cell-associated antigen in health and disease, whereas both the CD11bhi and the CD103+ dendritic cells ingest and traffic latex beads or soluble antigen [60]. Whether this is due to selective expression of receptors recognising apoptotic cells or a phenotypic switch after ingestion is not currently known. Therefore, clearance of apoptotic cells has profound influences on the ingesting cell. Though the outcome has predominantly been studied for macrophages, other cell types, particularly dendritic cells, are also likely to be affected.
Fig. 1

The many roles of apoptotic cell recognition and phagocytosis in immunity and infection. a Efferocytosis leads to removal of apoptotic cells without release of their content. When apoptotic cells are not engulfed in a timely manner, they undergo secondary necrosis and release necrotic cell debris which subsequently causes uncontrolled inflammatory activation of the innate immune system by the released ‘damage associated molecular patterns’ (DAMPS). b During apoptosis, cells expose phosphatidylserine (PtdSer) on the outer leaflet of their membranes, which is recognised by specific receptors expressed on phagocytes. Recognition of PtdSer by TAM receptors through bridging molecules Gas6 and Protein S triggers a signalling cascade which converges on upregulation of suppressor of cytokine signalling-1 and 3 (SOCS3), which act as negative regulators of the immune response. Activation of TAM receptors by apoptotic cells inhibits production of proinflammatory cytokines, such as TNFα and IL-6, while promoting expression of factors that suppress inflammation and promote tissue repair, including IL-10 and TGF-β. c Some enveloped viruses express PtdSer on their envelopes and use PtdSer recognition receptors, such as TAM and TIM receptor families, to promote infection of the host cells and evade the immune response. d During microbial infections with intracellular pathogens, induction of apoptosis of infected cells is one of the strategies of the host immune system to facilitate pathogen clearance. For example, in case of Mycobacterium tuberculosis (Mtb) infections, necrosis of infected cells leads to dissemination of bacteria, whereas engulfment of infected cells undergoing apoptosis allows for pathogen destruction

Cell turnover and clearance in the lung

In any tissue, cell turnover is a natural homeostatic process and occurs predominantly by apoptosis before loss of plasma membrane integrity. Timely removal of these apoptotic cells is critical to prevent autoimmune reactions to cellular constituents. However, the speed of turnover determines the requirements for the local phagocytic system in terms of its capacity to clear the accumulating apoptotic cells and is often governed by the local microenvironment and past inflammation history. In healthy murine and human lungs, airway macrophages make up 95 % of cells retrieved by bronchoalveolar lavage [2, 61]. They exist in a tolerant state due to interaction with proteins and receptors expressed by or secreted from the respiratory epithelium. Furthermore, mucus bathing the epithelium contains surfactant proteins that dampen macrophage responsiveness in health [62]. Chimeric mouse experiments show that resident airway macrophages have an unusually prolonged life span with negligible turnover even at 8 months in the absence of inflammation. This situation changes following their depletion during inflammation where replenishment from the periphery occurs, leading to a population of macrophages that are reported to have a shorter life span. Airway macrophage removal by irradiation leads to replenishment from the periphery and a higher turnover rate of approximately 30 days [63]. However, the fate of resident airway macrophages following pulmonary infection is not entirely clear. One study shows that macrophages recruited to the airways from the periphery during influenza infection contract by Fas-dependent apoptosis, while the number of resident airway macrophages remains unchanged [64], whereas another implies significant ablation of resident airway macrophages followed by replenishment from the interstitial pool [65]. Discrepancy might arise from the use of intranasal dye (that becomes diluted on cell division) or the depletion by irradiation with the lung protected by lead. In order to track definitively the fate of airway macrophages following influenza infection, the Flt3-Cre × Rosa26-LSL-YFP reporter mice would be useful as all bone marrow emigrants become YFP expressing and so mice do not require prior manipulation to distinguish resident versus recruited airway cells [66]. Like airway macrophages, epithelial cells similarly have a long half-life in health. Using reporter mice where ciliated cells and their progeny can be tracked across their lifetime, a half-life of 6 months in the trachea and 17 months in the bronchioles and terminal bronchioles has been estimated [67].

Taken together, these observations indicate that in homeostasis relatively small quantities of apoptotic cells appear in the airways due to slow turnover of the main cell populations residing in the healthy lung. It is therefore not surprising that lung phagocytes efficiently clear these scarce apoptotic cells even when their efferocytic function is partly disrupted. For example, deletion of Axl, which is highly expressed on murine airway macrophages, does not cause accumulation of necrotic cell debris and lung inflammation in the absence of accompanying infection despite significant impairment of the efferocytic function of airway macrophages [2]. Similarly, blockade of apoptotic cell uptake by airway epithelial cells through cell type-specific deletion of the small GTPase Rac1, which is required for efferocytosis mediated by several classes of engulfment receptors, does not affect the integrity and responses of the epithelial barrier without administration of exogenous apoptotic cells or induction of allergic airway inflammation [68].

Defective efferocytosis in chronic lung diseases

In health, apoptotic cells are essentially undetectable in the lung tissue [69], and immune cells infiltrating the airways which undergo apoptosis are rapidly cleared by airway macrophages in models of acute microbial infection-related lung inflammation [70]. Respiratory infections are therefore not associated with persistent accumulation of large quantities of apoptotic cells in the airspaces. However, increased numbers of dying cells are detected in the airspaces of patients with several aetiologically distinct chronic inflammatory lung diseases [71]. Although higher frequencies of apoptotic cells in these diseases might result either from elevated rates of apoptotic cell death or defects in apoptotic cell removal, experimental evidence suggests that reduced efficiency of efferocytosis, predominantly by airway macrophages, plays a key role in this pathological process [72, 73].

Chronic obstructive pulmonary disease

The most comprehensive analysis of defects in apoptotic cell clearance has been performed in chronic obstructive pulmonary disease (COPD), which is a chronic lung disease characterised by un-resolving inflammation due to accumulation of activated neutrophils and T cells causing small-airway obstruction, peribronchial fibrosis and/or destruction of airway walls (emphysema). These pathological processes lead to progressive destruction of lung parenchyma and, as a consequence, airflow limitation that is not fully reversible in patients with emphysema, and in other subtypes of COPD [74]. Historically, lung pathology in COPD was attributed to alterations in the protease/anti-protease balance and oxidative stress caused by cigarette smoking, which is the main risk factor for COPD. However, there is evidence that indicates an important role of aberrant apoptosis and apoptotic cell clearance in the lung damage observed in COPD [75]. Several reports demonstrate accumulation of apoptotic epithelial, endothelial and immune cells in the lungs of patients with COPD and/or emphysema [69, 76, 77], and induction of structural airway cell apoptosis is sufficient to cause emphysematous changes in mice [78].

In a series of elegant studies, Hodge and co-workers demonstrate that increases in the numbers of apoptotic cells detected in the lungs of patients with COPD can be attributed to significantly impaired efferocytic function of airway macrophages. Uptake of apoptotic bronchial epithelial cells and neutrophils is significantly reduced in bronchoalveolar lavage macrophages from patients with COPD compared to healthy controls [21, 22, 79], and this defect is more pronounced in COPD patients who currently smoke [22]. The observed reductions in efferocytic potential of airway macrophages in vitro correlate with the frequency of apoptotic bronchial epithelial cells isolated from bronchial brushings and are associated with altered expression of several proteins involved in apoptotic cell recognition and binding, including CD31, CD44 and LRP-1/CD91 [22]. Intriguingly, restoration of COPD airway macrophage efferocytic function by the macrolide antibiotic azithromycin does not correlate with changes in expression of these molecules [21]. Instead, it depends on PtdSer binding by airway macrophages [21], suggesting that deregulation of PtdSer-recognising receptors or bridging molecules might be responsible for defective apoptotic cell removal in COPD. Neither TAM nor TIM families of PtdSer recognition receptors have been studied in COPD so far but, surprisingly, increased expression of MerTK is observed on airway macrophages from cigarette smokers [18], which are also characterised by impaired apoptotic cell uptake compared to cells from healthy non-smokers [18, 22]. This observation indicates that upregulation of MerTK is not sufficient to restore the efforocytic function of airway macrophages to normal levels and other PtdSer receptors, such as Axl, which is highly expressed on mouse airway macrophages [2], might play a more prominent role.

Apart from potential alterations in PtdSer receptor expression and function, which require more detailed studies, several other mechanisms might be involved in efferocytosis defects observed in COPD. Significant impairment of apoptotic cell uptake by airway macrophages from smokers indicates an important role of oxidative stress caused by cigarette smoke components in this process [18, 22]. In mice, cigarette smoke exposure, which is sufficient to induce emphysema [80], significantly suppresses efferocytosis by airway macrophages in vivo and in vitro, and this effect is reversible by treatment with antioxidants or overexpression of extracellular superoxide dismutase [81, 82]. Macrophage phagocytosis of apoptotic cells is also inhibited by the alarmin high mobility group protein-1 (HMGB1) [83, 84], and elevated levels of HMGB1 both in the airways and peripheral blood of patients with COPD have recently been reported, negatively correlating with patient lung function [20, 85]. Since necrotic cells are the main source of extracellular HMGB1, a positive feedback loop might exist in COPD where apoptotic cells undergo secondary necrosis and release HMGB1, which further impairs the efferocytic function of airway macrophages. This in turn would lead to accumulation of greater amounts of necrotic debris and perpetuation of chronic inflammation. Finally, engulfment of apoptotic cells by macrophages is also regulated by the members of the collectin family of C-type lectins. The levels of mannose-binding lectin (MBL), which promotes apoptotic cell uptake in vitro [86], are reduced in the airways of patients with COPD and correlate with impaired macrophage efferocytosis [87, 88]. Surfactant protein A (SP-A) and SP-D, on the other hand, play a more complex role in apoptotic cell recognition in the lung. While homeostatic interaction of SP-A or SP-D with signal inhibitory regulatory protein-α (SIRPα) expressed on airway macrophages suppresses efferocytosis [89], opsonisation of apoptotic cells by SP-A or SP-D and interaction of this complex with LRP-1/CD91 enhances apoptotic cell uptake [29, 90]. The latter seems to play a more prominent role during chronic lung inflammation as SP-D levels are significantly reduced in patients with COPD [28, 91], potentially contributing to efferocytosis defects. Alternatively, downregulation of SP-D might represent a physiological response of the lung aimed at overcoming SIRPα-dependent suppression of macrophage efferocytic function in the presence of large amounts of dead cells, which fail to efficiently remove apoptotic cells from the COPD airways due to other phagocytosis defects.

Asthma

Asthma is an obstructive airway disease characterised by hyper-responsiveness and chronic inflammation of the respiratory tract. While neutrophils are a predominant cell type in the lungs of COPD patients, asthma represents eosinophil-dominant airway inflammation. Initial priming of the adaptive immune system by airway allergens leads to the activation of tissue-resident mast cells, which release a broad array of inflammatory mediators promoting migration of eosinophils into the airways [92]. Products of eosinophil degranulation, including major basic protein, eosinophil cationic protein and reactive oxygen species, are cytotoxic to epithelial cells and cause airway damage and tissue remodelling. Indeed, increased numbers of apoptotic epithelial cells have been detected in the lungs of patients with asthma compared to healthy individuals [93]. Apoptosis and subsequent uptake by phagocytes appear to be a predominant mechanism of eosinophil removal from the airways [94, 95], and glucocorticoids, which are commonly used to control inflammation in asthma, induce eosinophil apoptosis [96]. These observations indicate that high efficiency of the phagocytic system is required for removal of large quantities of apoptotic eosinophils and bronchial epithelial cells from the airways of patients with asthma and raise the possibility that defects in efferocytosis might prevent resolution of lung inflammation.

Initial studies by Hyunh et al. demonstrate that airway macrophages from patients with severe asthma contain reduced numbers of phagocytic bodies compared to healthy donors and patients with mild/moderate asthma and are defective in phagocytosing apoptotic Jurkat T cells in vitro [97]. Failure of airway macrophages from patients with severe asthma to efficiently clear apoptotic cells is associated with reduced production of anti-inflammatory eicosanoids [97], suggesting that defects in efferocytosis might contribute to perpetuation of inflammation in asthma, not only through secondary necrosis of apoptotic cells, but also by reduced release of regulatory mediators that are normally produced upon recognition of apoptotic cells by airway macrophages. More recently, it has been shown that efferocytosis of apoptotic bronchial epithelial cells by airway macrophages isolated from induced sputum of patients with non-eosinophilic asthma is significantly reduced compared with patients with eosinophilic asthma, and the degree of uptake impairment is comparable to that observed in COPD [98]. This observation might partly explain the persistent neutrophilia and aberrant innate immune responses in this subgroup of patients [99]. Efferocytosis defects in asthma are associated not only with the subtype of airway inflammation but also with the BMI index: airway macrophages from obese patients with asthma, which typically suffer from more severe disease symptoms [100], are characterised by significantly reduced numbers of phagocytic bodies compared to non-obese asthmatics [101]. Notably, defective efferocytic function in obese asthmatics is not restricted to the site of inflammation as decreased uptake of beads mimicking apoptotic cells is also observed in peripheral blood monocytes isolated from these patients, correlating with reduced glucocorticoid responsiveness [101].

While these reports provide clear evidence that removal of apoptotic cells is defective in asthma, in particular in certain disease subtypes, additional studies are needed to characterise the molecular mechanisms underlying the observed defects. Even though potential changes in expression and function of receptors recognising apoptotic cells on airway macrophages have not been formally studied in asthma, it is important to note that the TIM receptor family member TIM-1, which is preferentially expressed on specific lymphocyte populations, is an important susceptibility gene for allergic asthma [102]. Targeting TIM-1 modulates airway inflammation in mouse models of airway hyper-responsiveness at least in part through TIM-1-dependent interaction of NKT cells with PtdSer on the surface of apoptotic cells [103, 104]. These observations suggest that recognition of PtdSer by immune cells that do not phagocytose apoptotic cells also has profound effects on the development of chronic lung inflammation. They also indicate that future studies of molecules involved in apoptotic cell binding in asthma should not be restricted to analyses of airway macrophages as the main contributors to apoptotic cell clearance from the inflamed airways. Interestingly, not only efferocytosis but also engulfment of bacteria by airway macrophages is impaired in asthma [105]. This finding indicates that alterations in the intracellular molecular machinery regulating phagocytosis rather than changes in expression of receptors recognising apoptotic cells might be responsible for the observed phagocytosis defects.

Finally, while previous studies have solely focused on efferocytosis by airway macrophages, mounting evidence suggests that bronchial epithelial cells might be equally important in clearing apoptotic cells from the inflamed airways. Even though epithelial cells are not professional phagocytes, they efficiently engulf apoptotic eosinophils, but not neutrophils [94, 106]. Animal studies demonstrate a critical role for airway epithelial cells in the removal of apoptotic cells from the inflamed lung and, as a consequence, control of inflammatory responses in the murine model of allergic airway hyper-responsiveness [68]. Future studies in humans are therefore necessary to characterise the relative contributions of airway macrophages and bronchial epithelial cells to defects in apoptotic cell removal in asthma and to identify therapeutic strategies which could restore and/or promote the efferocytic function of both cell types, as well as activate anti-inflammatory transcriptional programmes associated with apoptotic cell recognition.

Cystic fibrosis

Cystic fibrosis (CF) is a heritable disorder caused by mutation in the CF transmembrane conductance regulator (CFTR) and characterised by severe pulmonary manifestations. Impaired mucociliary clearance in CF patients prevents elimination of bacteria from the lung, leading to persistent neutrophilic inflammation and progressive, irreversible damage of the airways [107]. Similar to other lung diseases associated with chronic inflammation, both accumulation of apoptotic cells in the airways and reduced numbers of phagocytic bodies within sputum macrophages are observed in patients with CF compared to control patients with chronic bronchitis [25]. Mechanistically, degranulation products of immune cells are partly responsible for efferocytosis defects in CF as neutrophil elastase present in the airway fluid of CF patients selectively cleaves PtdSer recognition receptors and suppresses apoptotic cell removal by airway macrophages [25]. Other potential mechanisms contributing to impaired apoptotic cell clearance in CF involve the release of HMGB1 which, similar to COPD, is elevated in sputum samples from CF patients [108] and effects of bacterial products on airway macrophages. Pseudomonas aeruginosa infections are common in CF and represent an important cause of mortality in CF lung manifestations. In vitro, P. aeruginosa toxic metabolite pyocyanin and the polysaccharide alginate inhibit apoptotic cell uptake by macrophages [109, 110], though the relevance of this mechanism in patients has yet to be demonstrated. Interestingly, animal studies indicate that airway epithelial cells in CF might also be deficient in phagocytic functions.

While defective efferocytosis by airway macrophages in CF patients is a consequence of the ongoing inflammatory response and/or microbial infection, impaired apoptotic cell uptake by epithelial cells might be directly related to the lack of CFTR expression. CFTR-deficient epithelial cells express significantly increased levels of RhoA, which is a negative regulator of efferoctyosis, and RhoA inhibition restores their phagocytic function [111]. It remains to be determined if a similar mechanism regulates bronchial epithelial cell efferocytosis in patients with CF.

Pulmonary fibrosis

Elevated levels of apoptotic cells and reduced frequencies of phagocytic bodies within bronchoalveolar lavage macrophages have also been reported in patients with idiopathic pulmonary fibrosis (IPF) [112]. IPF is an interstitial lung disease characterised by epithelial injury that is followed by aberrant alveolar wound repair and scar formation, which ultimately lead to respiratory failure and death. IPF is frequently accompanied by chronic neutrophilic inflammation [113]. Interestingly, intratracheal instillation of apoptotic cells ameliorates fibrosis and inflammation in bleomycin-induced lung injury in mice [58, 114], indicating that signalling triggered by apoptotic cell recognition may play a protective role in lung diseases associated with dysregulated healing processes. The anti-fibrotic effects of apoptotic cells in this model are dependent on the induction of PPARγ expression in airway macrophages and increased production of hepatocyte growth factor (HGF), which plays a key role in alveolar epithelial repair upon lung injury [58, 114]. These observations suggest that defects in efferocytosis in IPF patients may be responsible not only for inefficient clearance of apoptotic cells but also for diminished production of factors that support tissue repair without fibrosis.

Collectively, the data from patients with asthma, COPD, CF and pulmonary fibrosis indicate that defective apoptotic cell clearance in lung diseases is not specific for individual diagnoses but rather represents a general hallmark of chronic inflammation. Although several mechanisms contributing to these defects have been proposed, it remains to be verified whether impairment of efferocytosis might be a direct cause of chronic inflammation, or is a consequence to the ongoing inflammatory processes that contributes to chronicity and prevents resolution. The latter model is supported by the observation that mice lacking the TAM receptor Axl do not develop spontaneous lung inflammation despite defects in apoptotic cell uptake by airway macrophages [2], but more detailed analyses of regulation and function of PtdSer recognition receptors in the human lung are required. Finally, because recognition of apoptotic cells by PtdSer-recognising receptors activates downstream signalling pathways even without engulfment [46], future studies are needed to verify whether activation of transcriptional programmes triggered by recognition of apoptotic cells is also altered in chronic lung diseases and, if so, how they can be manipulated in the clinic by specific modulators of PtdSer recognition receptors.

Efferocytosis in microbial infection of the lung

While in sterile inflammation recognition of apoptotic cells by the immune system typically results in suppression of the ongoing inflammatory response, the complexity of this process and its biological effects greatly increase in the context of microbial infections. First, some enveloped viruses use PtdSer receptors to promote their entry into the host cells and facilitate infection and immune evasion [115]. The interaction between PtdSer exposed on the surface of the viral envelope and members of the TAM and TIM receptor families expressed on the target cell enables proximity to specific entry receptors and enhances engulfment of the virus [116] (Fig. 1c). The relevance of this process, called ‘apoptotic mimicry’, has recently been confirmed for a broad range of virions, including Ebola and dengue viruses [117, 118]. Thus far, however, little is known about potential roles of this entry mechanism in pulmonary viral infections. The observation that the kinetics of influenza H1N1 virus clearance was unaffected in Axl-deficient mice indirectly indicates that Axl is not important for control of this infection [2], though Axl-H1N1 interaction has not been formally tested. Similarly, although TIM1 promotes internalisation and replication of several enveloped viruses, TIM1-mediated entry does not lead to a productive infection by influenza H7N1 and severe acute respiratory syndrome (SARS) coronavirus [117], arguing against an important role of apoptotic mimicry in viral lung diseases.

Second, many pathogens survive intracellularly, and phagocytosis of infected host cells undergoing apoptosis has diverse consequences for pathogen survival and immune response of the host [119]. One of the main strategies of the immune system to control intracellular infections is through induction of apoptosis of infected cells, which are then engulfed and destroyed together with the pathogen by phagocytes (Fig. 1d). However, in some cases, efferocytosis of infected cells is used by intracellular pathogens, such as the parasite Leishmania major, to evade the immune response and gain entry into the new cellular host [119]. Among pathogens important in respiratory diseases, the role of efferocytosis has been most thoroughly studied in the context of Mycobacterium tuberculosis infections. M. tuberculosis infects macrophages and induces necrosis of the host cell to avoid clearance by the immune system and disseminate [120]. Interestingly, M. tuberculosis-infected mouse macrophages which die by apoptosis are rapidly efferocytosed by uninfected macrophages, leading to bacterial killing and elimination [121]. This bactericidal effect is dependent on efferocytosis, as the uptake of naked M. tuberculosis does not allow for lysosome recruitment to the bacteria-containing phagosome, and inhibition of apoptotic cell uptake with a TIM-4-blocking antibody prevents bacterial control in vitro and increases bacterial burden in the lungs in vivo [121]. The observation that bactericidal activity of macrophages infected with Streptococcus pneumoniae is dependent on induction of macrophage apoptosis suggests that a similar mechanism might be involved in controlling infection with this bacterium [122], though the involvement of efferocytosis in this process has not been formally proven. Engulfment of macrophage-derived apoptotic vesicles also plays a critical, though indirect, role in the adaptive immune response against M. tuberculosis: annexin A1-dependent uptake of apoptotic cells by dendritic cells is required for cross-presentation and generation of M. tuberculosis-specific CD8 T cell response and bacterial clearance from the lung [123].

The antimicrobial role of apoptotic cell clearance in pulmonary infections is not restricted to bacteria as the influenza A virus induces apoptosis of epithelial cells upon infection and engulfment of influenza A-infected cells by macrophages is associated with reduction of viral titres [124]. On the other hand, infection of macrophages with Francisella novicida, a member of the Francisellaceae family of intracellular bacteria which cause pulmonary inflammation associated with necrotic infiltrates in the lung, reduces their efferocytic function, potentially contributing to the accumulation of necrotic cell debris and exacerbation of disease [125].

Taken together, these studies suggest that efferocytosis is not only a constitutive function of macrophages required for maintaining immune homeostasis in health and during inflammatory response but also an important antimicrobial effector mechanism. However, it has to be noted that apart from bactericidal activity against specific pathogens, the anti-inflammatory signal associated with apoptotic cell uptake by phagocytes might prevent the mounting of an efficient immune response in the context of other lung infections. Prior exposure of mouse airway macrophages to apoptotic cells results in suppression of FcR-mediated phagocytosis and killing of bacteria, and intrapulmonary administration of apoptotic cells causes significant impairment of S. pneumoniae clearance from the infected lung [56]. Suppression of antimicrobial responses of airway macrophages is also augmented by glucocorticoids, which promote efferocytosis, and treatment of mice with apoptotic cells in the presence of glucocorticoids is associated with elevated bacterial burden in the lungs [126]. Even though validation of these observations in human systems is necessary, they clearly indicate that efferocytosis plays a dual role in lung infections: while efficient apoptotic cell uptake is required for resolution of the inflammatory response and elimination of certain intracellular pathogens, the anti-inflammatory programmes activated upon prolonged exposure to apoptotic cells might increase susceptibility to secondary infections and infection-related exacerbations of chronic inflammatory lung diseases.

Targeting defective apoptotic cell clearance in lung diseases

In light of the importance of effercotysis in resolution of inflammation and the reported defects in apoptotic cell removal in chronic inflammatory lung diseases, it is not surprising that evaluation of potential therapeutic strategies aimed at enhancing apoptotic cell uptake gained a lot of attention in recent years [72, 73]. Strikingly, glucocorticoids, which are the most commonly used class of drugs in the treatment of asthma and COPD, increase apoptotic cell engulfment by macrophages in vitro [127] and restore the efferocytic function of airway macrophages from patients with severe asthma [97]. Upregulation of the TAM receptor MerTK [128, 129] and downregulation of SIRPα [130] might be responsible for the pro-efferocytic activity of glucocorticoids in macrophages. However, it remains unknown whether promotion of apoptotic cell clearance significantly contributes to the anti-inflammatory effects of glucocorticoids in patients with lung diseases. More systematic analyses of apoptotic cell accumulation and efferocytic functions of airway macrophages before and after glucocorticoid therapy in responders and non-responders are therefore necessary to address this question.

Some classes of medications widely used in the clinic for other indications also promote efferocytosis. The antibiotic azithromycin increases phagocytosis of apoptotic cells by human airway macrophages in vitro [21, 131], and significant improvement of the efferocytic function of airway macrophages from COPD patients after oral treatment with azithromycin has been reported [28]. In light of recent evidence that azithromycin reduces the frequency of exacerbations in COPD patients [132], it is tempting to speculate that at least part of the immunomodulatory activities of macrolide antibiotics can be attributed to their effects on apoptotic cell clearance. Similarly, PPARγ agonists, which are used as insulin sensitizers in diabetes mellitus, but also display broad anti-inflammatory effects, promote efferocytosis by airway macrophages in vitro and ameliorate disease symptoms in animal models of pulmonary inflammation [133, 134]. Enhancement of apoptotic cell engulfment is also observed after treatment of macrophages from COPD patients with simvastatin [135], a member of the statin family of cholesterol-lowering drugs, and retrospective studies suggested that statins might reduce the risk of COPD exacerbations and mortality [136, 137]. More recently however, in a large randomised clinical trial, simvastatin treatment had no effect on exacerbation rates in COPD patients [138], though the efferocytic function of airway macrophages was not analysed in this study. It remains an open question if patients with COPD can be stratified to identify a subgroup of patients that responds to statin treatment and whether this is related to effects on apoptotic cell clearance.

Finally, the observations that aberrant expression and activity of the TAM receptor Axl has an oncogenic function in haematological and epithelial malignancies triggered the interest in targeting the activity of PtdSer recognition receptors, and a small molecule inhibitor of Axl is currently in phase I clinical trials [139]. However, preclinical studies indicate that pharmacological modulators of PtdSer recognition receptors might have a significant impact on the immune system, especially in the context of lung immunopathology. In light of the critical role of Axl in resolution of lung inflammation upon influenza infection [2], any attempts to target Axl activity systemically should proceed with caution due to potential adverse events related to exaggerated inflammatory responses to respiratory infections. Similar to Axl, MerTK signalling is also required for silencing of lung inflammation: inhibition of MerTK proteolytic cleavage by the ADAM17 inhibitor TAPI-0 restores MerTK expression and attenuates inflammation during LPS-induced lung injury [140], whereas administration of a MerTK blocking antibody has the opposite effect [141]. These results suggest that activating antibodies or compounds which prevent shedding of TAM receptors could be beneficial in the context chronic lung diseases. Indeed, TAM receptors can be activated independently of apoptotic cell engulfment by specific antibodies [46, 142], though their effects have not been tested in models of lung inflammation. In that regard, it is noteworthy that activation of TAM receptors leads to shedding of their extracellular domains and soluble forms of TAM receptors can act as decoy receptors and suppress apoptotic cell engulfment by macrophages [143]. Although alterations in the levels of soluble TAM receptors are noted in several pathologies [144, 145], their physiological role is still poorly understood. It remains unknown if administration of antibodies targeting TAM receptors would cause their sequestration and what consequences it would have for the immune homeostasis of the lung.

Conclusions

Since the initial discovery of defects in apoptotic cell clearance in asthma and COPD, great progress has been made in our understanding of the molecular mechanisms of efferocytosis and several new processes through which efferocytosis modulates host immune responses have been characterised (Fig. 1). Consequently, new questions have emerged regarding the role of apoptotic cell removal in lung homeostasis and the most important of them are listed in Box 1. Future studies addressing these questions, especially attempts to therapeutically manipulate efferocytosis in the clinic, should be designed in the context of the multiple roles of apoptotic cell phagocytosis in resolution of inflammation and microbial infections.

Box 1. Future questions in apoptotic cell removal in the airspaces

• Does efferocytosis polarise airway macrophages to an M2 phenotype or are M2 polarised airway macrophages better at efferocytosis?

• What is the impact of the tissue microenvironment on apoptotic cell recognition receptor repertoires and outcome of their ligation?

• Is homeostatic apoptotic cell clearance different in requirements and consequences to clearance of cells during inflammation?

• What is the impact of the altered lung environment in asthma, COPD and CF on apoptotic cell clearance?

• Does cooperation between different apoptotic cell clearance receptors introduce heterogeneity in outcome?

• Under what circumstances is efferocytosis by non-professional phagocytes important?

• To what extent do PtdSer-expressing pathogens sculpt immunity?

• Should there be an effort to develop therapeutics that manipulate the efferocytic pathway?

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Arandjelovic S, Ravichandran KS (2015) Phagocytosis of apoptotic cells in homeostasis. Nat Immunol 16:907–917. doi: 10.1038/ni.3253 PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Fujimori T, Grabiec AM, Kaur M, Bell TJ, Fujino N, Cook PC et al (2015) The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol 8:1021–1030. doi: 10.1038/mi.2014.129 PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282–286. doi: 10.1038/nature08296 PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE et al (2008) CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112:5026–5036. doi: 10.1182/blood-2008-06-162404 PubMedCrossRefGoogle Scholar
  5. 5.
    Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK et al (2003) Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113:717–730PubMedCrossRefGoogle Scholar
  6. 6.
    Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R et al (2008) Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. FASEB J 22:2629–2638. doi: 10.1096/fj.08-107169 PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Miksa M, Amin D, Wu R, Ravikumar TS, Wang P (2007) Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages. Mol Med 13:553–560. doi: 10.2119/2007-00019.Miksa PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Peter C, Wesselborg S, Herrmann M, Lauber K (2010) Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis 15:1007–1028. doi: 10.1007/s10495-010-0472-1 PubMedCrossRefGoogle Scholar
  9. 9.
    Leventis PA, Grinstein S (2010) The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys 39:407–427. doi: 10.1146/annurev.biophys.093008.131234 PubMedCrossRefGoogle Scholar
  10. 10.
    Asano K, Miwa M, Miwa K, Hanayama R, Nagase H, Nagata S et al (2004) Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice. J Exp Med 200:459–467. doi: 10.1084/jem.20040342 PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Schroit AJ, Madsen JW, Tanaka Y (1985) In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 260:5131–5138PubMedGoogle Scholar
  12. 12.
    Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S (2014) Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 344:1164–1168. doi: 10.1126/science.1252809 PubMedCrossRefGoogle Scholar
  13. 13.
    Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S (2013) Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 341:403–406. doi: 10.1126/science.1236758 PubMedCrossRefGoogle Scholar
  14. 14.
    Ravichandran KS (2010) Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 207:1807–1817. doi: 10.1084/jem.20101157 PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Barclay AN, Van den Berg TK (2014) The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 32:25–50. doi: 10.1146/annurev-immunol-032713-120142 PubMedCrossRefGoogle Scholar
  16. 16.
    Brown S, Heinisch I, Ross E, Shaw K, Buckley CD, Savill J (2002) Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 418:200–203. doi: 10.1038/nature00811 PubMedCrossRefGoogle Scholar
  17. 17.
    Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F (2012) Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119:2799–2809. doi: 10.1182/blood-2011-08-372425 PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Kazeros A, Harvey BG, Carolan BJ, Vanni H, Krause A, Crystal RG (2008) Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers. Am J Respir Cell Mol Biol 39:747–757. doi: 10.1165/rcmb.2007-0306OC PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Robinson AB, Johnson KD, Bennion BG, Reynolds PR (2012) RAGE signaling by alveolar macrophages influences tobacco smoke-induced inflammation. Am J Physiol Lung Cell Mol Physiol 302:L1192–L1199. doi: 10.1152/ajplung.00099.2012 PubMedCrossRefGoogle Scholar
  20. 20.
    Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M et al (2010) Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:917–927. doi: 10.1164/rccm.200903-0340OC PubMedCrossRefGoogle Scholar
  21. 21.
    Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN (2006) Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 28:486–495. doi: 10.1183/09031936.06.00001506 PubMedCrossRefGoogle Scholar
  22. 22.
    Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN (2007) Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 37:748–755. doi: 10.1165/rcmb.2007-0025OC PubMedCrossRefGoogle Scholar
  23. 23.
    Wu K, Byers DE, Jin X, Agapov E, Alexander-Brett J, Patel AC et al (2015) TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med 212:681–697. doi: 10.1084/jem.20141732 PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Hoogerwerf JJ, de Vos AF, van’t Veer C, Bresser P, de Boer A, Tanck MW et al (2010) Priming of alveolar macrophages upon instillation of lipopolysaccharide in the human lung. Am J Respir Cell Mol Biol 42:349–356. doi: 10.1165/rcmb.2008-0362OC PubMedCrossRefGoogle Scholar
  25. 25.
    Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK et al (2002) Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 109:661–670. doi: 10.1172/JCI13572 PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H (2013) Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol 49:503–510. doi: 10.1165/rcmb.2013-0086MA PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Pons AR, Noguera A, Blanquer D, Sauleda J, Pons J, Agusti AG (2005) Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir J 25:647–652. doi: 10.1183/09031936.05.00062304 PubMedCrossRefGoogle Scholar
  28. 28.
    Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M et al (2008) Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:139–148. doi: 10.1164/rccm.200711-1666OC PubMedCrossRefGoogle Scholar
  29. 29.
    Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M et al (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169:3978–3986. doi: 10.4049/jimmunol.169.7.3978 PubMedCrossRefGoogle Scholar
  30. 30.
    Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201:647–657. doi: 10.1084/jem.20041611 PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Murakami Y, Tian L, Voss OH, Margulies DH, Krzewski K, Coligan JE (2014) CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition. Cell Death Differ 21:1746–1757. doi: 10.1038/cdd.2014.86 PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Friggeri A, Banerjee S, Biswas S, de Freitas A, Liu G, Bierhaus A et al (2011) Participation of the receptor for advanced glycation end products in efferocytosis. J Immunol 186:6191–6198. doi: 10.4049/jimmunol.1004134 PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Park SY, Jung MY, Kim HJ, Lee SJ, Kim SY, Lee BH et al (2008) Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ 15:192–201. doi: 10.1038/sj.cdd.4402242 PubMedCrossRefGoogle Scholar
  34. 34.
    Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z et al (2007) BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450:430–434. doi: 10.1038/nature06329 PubMedCrossRefGoogle Scholar
  35. 35.
    Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S (2007) Identification of Tim4 as a phosphatidylserine receptor. Nature 450:435–439. doi: 10.1038/nature06307 PubMedCrossRefGoogle Scholar
  36. 36.
    Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE et al (2007) TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27:927–940. doi: 10.1016/j.immuni.2007.11.011 PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Lemke G (2013) Biology of the TAM receptors. Cold Spring Harb Perspect Biol 5:a009076. doi: 10.1101/cshperspect.a009076 PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C et al (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80:661–670PubMedCrossRefGoogle Scholar
  39. 39.
    Ravichandran KS (2011) Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 35:445–455. doi: 10.1016/j.immuni.2011.09.004 PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H et al (1996) Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 271:30022–30027PubMedCrossRefGoogle Scholar
  41. 41.
    Park D, Hochreiter-Hufford A, Ravichandran KS (2009) The phosphatidylserine receptor TIM-4 does not mediate direct signaling. Curr Biol 19:346–351. doi: 10.1016/j.cub.2009.01.042 PubMedCrossRefGoogle Scholar
  42. 42.
    Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD (1998) Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392:505–509. doi: 10.1038/33169 PubMedCrossRefGoogle Scholar
  43. 43.
    Mazaheri F, Breus O, Durdu S, Haas P, Wittbrodt J, Gilmour D et al (2014) Distinct roles for BAI1 and TIM-4 in the engulfment of dying neurons by microglia. Nat Commun 5:4046. doi: 10.1038/ncomms5046 PubMedCrossRefGoogle Scholar
  44. 44.
    Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC et al (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109:1144–1156. doi: 10.1111/j.1471-4159.2009.06042.x PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Headland SE, Norling LV (2015) The resolution of inflammation: principles and challenges. Semin Immunol 27:149–160. doi: 10.1016/j.smim.2015.03.014 PubMedCrossRefGoogle Scholar
  46. 46.
    Zagorska A, Traves PG, Lew ED, Dransfield I, Lemke G (2014) Diversification of TAM receptor tyrosine kinase function. Nat Immunol 15:920–928. doi: 10.1038/ni.2986 PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Lew ED, Oh J, Burrola PG, Lax I, Zagorska A, Traves PG et al. (2014) Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife 3. doi: 10.7554/eLife.03385
  48. 48.
    Subramanian M, Hayes CD, Thome JJ, Thorp E, Matsushima GK, Herz J et al (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296–1308. doi: 10.1172/JCI72051 PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G (2007) TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131:1124–1136. doi: 10.1016/j.cell.2007.10.034 PubMedCrossRefGoogle Scholar
  50. 50.
    Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 390:350–351. doi: 10.1038/37022 PubMedCrossRefGoogle Scholar
  51. 51.
    Chung EY, Liu J, Homma Y, Zhang Y, Brendolan A, Saggese M et al (2007) Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 27:952–964. doi: 10.1016/j.immuni.2007.11.014 PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    McDonald PP, Fadok VA, Bratton D, Henson PM (1999) Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells. J Immunol 163:6164–6172PubMedGoogle Scholar
  53. 53.
    Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC (2010) TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J Leukoc Biol 87:869–875. doi: 10.1189/jlb.0909610 PubMedCrossRefGoogle Scholar
  54. 54.
    Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101:890–898. doi: 10.1172/JCI1112 PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Savill J, Hogg N, Ren Y, Haslett C (1992) Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90:1513–1522. doi: 10.1172/JCI116019 PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Medeiros AI, Serezani CH, Lee SP, Peters-Golden M (2009) Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. J Exp Med 206:61–68. doi: 10.1084/jem.20082058 PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Huynh ML, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109:41–50. doi: 10.1172/JCI11638 PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Yoon YS, Kim SY, Kim MJ, Lim JH, Cho MS, Kang JL (2015) PPARgamma activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines. Mucosal Immunol 8:1031–1046. doi: 10.1038/mi.2014.130 PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Ren G, Su J, Zhao X, Zhang L, Zhang J, Roberts AI et al (2008) Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-gamma and nitric oxide. J Immunol 181:3277–3284PubMedCrossRefGoogle Scholar
  60. 60.
    Desch AN, Randolph GJ, Murphy K, Gautier EL, Kedl RM, Lahoud MH et al (2011) CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med 208:1789–1797. doi: 10.1084/jem.20110538 PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Balbo P, Silvestri M, Rossi GA, Crimi E, Burastero SE (2001) Differential role of CD80 and CD86 on alveolar macrophages in the presentation of allergen to T lymphocytes in asthma. Clin Exp Allergy 31:625–636PubMedCrossRefGoogle Scholar
  62. 62.
    Hussell T, Bell TJ (2014) Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 14:81–93. doi: 10.1038/nri3600 PubMedCrossRefGoogle Scholar
  63. 63.
    Murphy J, Summer R, Wilson AA, Kotton DN, Fine A (2008) The prolonged life-span of alveolar macrophages. Am J Respir Cell Mol Biol 38:380–385. doi: 10.1165/rcmb.2007-0224RC PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Janssen WJ, Barthel L, Muldrow A, Oberley-Deegan RE, Kearns MT, Jakubzick C et al (2011) Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am J Respir Crit Care Med 184:547–560. doi: 10.1164/rccm.201011-1891OC PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Ghoneim HE, Thomas PG, McCullers JA (2013) Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 191:1250–1259. doi: 10.4049/jimmunol.1300014 PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Schulz C, Gomez PE, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K et al (2012) A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336:86–90. doi: 10.1126/science.1219179 PubMedCrossRefGoogle Scholar
  67. 67.
    Rawlins EL, Hogan BL (2008) Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol 295:L231–L234. doi: 10.1152/ajplung.90209.2008 PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Juncadella IJ, Kadl A, Sharma AK, Shim YM, Hochreiter-Hufford A, Borish L et al (2013) Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 493:547–551. doi: 10.1038/nature11714 PubMedCrossRefGoogle Scholar
  69. 69.
    Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF (2001) Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 163:737–744. doi: 10.1164/ajrccm.163.3.2002117 PubMedCrossRefGoogle Scholar
  70. 70.
    Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J et al (2003) Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167:171–179. doi: 10.1164/rccm.200207-698OC PubMedCrossRefGoogle Scholar
  71. 71.
    Schmidt EP, Tuder RM (2010) Role of apoptosis in amplifying inflammatory responses in lung diseases. J Cell Death 2010:41–53. doi: 10.4137/JCD.S5375 PubMedPubMedCentralGoogle Scholar
  72. 72.
    Krysko O, Vandenabeele P, Krysko DV, Bachert C (2010) Impairment of phagocytosis of apoptotic cells and its role in chronic airway diseases. Apoptosis 15:1137–1146. doi: 10.1007/s10495-010-0504-x PubMedCrossRefGoogle Scholar
  73. 73.
    McCubbrey AL, Curtis JL (2013) Efferocytosis and lung disease. Chest 143:1750–1757. doi: 10.1378/chest.12-2413 PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183–192. doi: 10.1038/nri2254 PubMedCrossRefGoogle Scholar
  75. 75.
    Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG (2006) Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 7:53. doi: 10.1186/1465-9921-7-53 PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Imai K, Mercer BA, Schulman LL, Sonett JR, D’Armiento JM (2005) Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J 25:250–258. doi: 10.1183/09031936.05.00023704 PubMedCrossRefGoogle Scholar
  77. 77.
    Makris D, Vrekoussis T, Izoldi M, Alexandra K, Katerina D, Dimitris T et al (2009) Increased apoptosis of neutrophils in induced sputum of COPD patients. Respir Med 103:1130–1135. doi: 10.1016/j.rmed.2009.03.002 PubMedCrossRefGoogle Scholar
  78. 78.
    Aoshiba K, Yokohori N, Nagai A (2003) Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 28:555–562. doi: 10.1165/rcmb.2002-0090OC PubMedCrossRefGoogle Scholar
  79. 79.
    Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M (2003) Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 81:289–296. doi: 10.1046/j.1440-1711.2003.t01-1-01170.x PubMedCrossRefGoogle Scholar
  80. 80.
    Fricker M, Deane A, Hansbro PM (2014) Animal models of chronic obstructive pulmonary disease. Expert Opin Drug Discov 9:629–645. doi: 10.1517/17460441.2014.909805 PubMedCrossRefGoogle Scholar
  81. 81.
    Hodge S, Matthews G, Mukaro V, Ahern J, Shivam A, Hodge G et al (2011) Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am J Respir Cell Mol Biol 44:673–681. doi: 10.1165/rcmb.2009-0459OC PubMedCrossRefGoogle Scholar
  82. 82.
    Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL et al (2009) Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med 179:1011–1021. doi: 10.1164/rccm.200807-1148OC PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X et al (2008) High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 181:4240–4246. doi: 10.4049/jimmunol.181.6.4240 PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Friggeri A, Yang Y, Banerjee S, Park YJ, Liu G, Abraham E (2010) HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am J Physiol Cell Physiol 299:C1267–C1276. doi: 10.1152/ajpcell.00152.2010 PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Hou C, Zhao H, Liu L, Li W, Zhou X, Lv Y et al (2011) High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med 17:807–815. doi: 10.2119/molmed.2010.00173 PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA et al (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 194:781–795. doi: 10.1084/jem.194.6.781 PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Hodge S, Matthews G, Dean MM, Ahern J, Djukic M, Hodge G et al (2010) Therapeutic role for mannose-binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol 42:235–242. doi: 10.1165/rcmb.2008-0486OC PubMedCrossRefGoogle Scholar
  88. 88.
    Tran HB, Ahern J, Hodge G, Holt P, Dean MM, Reynolds PN et al (2014) Oxidative stress decreases functional airway mannose binding lectin in COPD. PLoS One 9, e98571. doi: 10.1371/journal.pone.0098571 PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Janssen WJ, McPhillips KA, Dickinson MG, Linderman DJ, Morimoto K, Xiao YQ et al (2008) Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am J Respir Crit Care Med 178:158–167. doi: 10.1164/rccm.200711-1661OC PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Schagat TL, Wofford JA, Wright JR (2001) Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol 166:2727–2733. doi: 10.4049/jimmunol.166.4.2727 PubMedCrossRefGoogle Scholar
  91. 91.
    Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA et al (2008) Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 9:13. doi: 10.1186/1465-9921-9-13 PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Lambrecht BN, Hammad H (2015) The immunology of asthma. Nat Immunol 16:45–56. doi: 10.1038/ni.3049 PubMedCrossRefGoogle Scholar
  93. 93.
    Bucchieri F, Puddicombe SM, Lordan JL, Richter A, Buchanan D, Wilson SJ et al (2002) Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am J Respir Cell Mol Biol 27:179–185. doi: 10.1165/ajrcmb.27.2.4699 PubMedCrossRefGoogle Scholar
  94. 94.
    Sexton DW, Blaylock MG, Walsh GM (2001) Human alveolar epithelial cells engulf apoptotic eosinophils by means of integrin- and phosphatidylserine receptor-dependent mechanisms: a process upregulated by dexamethasone. J Allergy Clin Immunol 108:962–969. doi: 10.1067/mai.2001.119414 PubMedCrossRefGoogle Scholar
  95. 95.
    Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ (1996) Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 154:237–243. doi: 10.1164/ajrccm.154.1.8680686 PubMedCrossRefGoogle Scholar
  96. 96.
    Felton JM, Lucas CD, Rossi AG, Dransfield I (2014) Eosinophils in the lung—modulating apoptosis and efferocytosis in airway inflammation. Front Immunol 5:302. doi: 10.3389/fimmu.2014.00302 PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA et al (2005) Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 172:972–979. doi: 10.1164/rccm.200501-035OC PubMedCrossRefGoogle Scholar
  98. 98.
    Simpson JL, Gibson PG, Yang IA, Upham J, James A, Reynolds PN et al (2013) Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin Exp Allergy 43:29–35. doi: 10.1111/j.1365-2222.2012.04075.x PubMedCrossRefGoogle Scholar
  99. 99.
    Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG (2007) Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 62:211–218. doi: 10.1136/thx.2006.061358 PubMedCrossRefGoogle Scholar
  100. 100.
    Juel CT, Ulrik CS (2013) Obesity and asthma: impact on severity, asthma control, and response to therapy. Respir Care 58:867–873. doi: 10.4187/respcare.02202 PubMedCrossRefGoogle Scholar
  101. 101.
    Fernandez-Boyanapalli R, Goleva E, Kolakowski C, Min E, Day B, Leung DY et al (2013) Obesity impairs apoptotic cell clearance in asthma. J Allergy Clin Immunol 131(1041–7):1047. doi: 10.1016/j.jaci.2012.09.028 Google Scholar
  102. 102.
    McIntire JJ, Umetsu DT, DeKruyff RH (2004) TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin Immunopathol 25:335–348. doi: 10.1007/s00281-003-0141-3 PubMedCrossRefGoogle Scholar
  103. 103.
    Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH (2010) TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 235:172–189. doi: 10.1111/j.0105-2896.2010.00903.x PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Lee HH, Meyer EH, Goya S, Pichavant M, Kim HY, Bu X et al (2010) Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J Immunol 185:5225–5235. doi: 10.4049/jimmunol.1001116 PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Fitzpatrick AM, Holguin F, Teague WG, Brown LA (2008) Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol 121:1372.e3–1378. doi: 10.1016/j.jaci.2008.03.008 CrossRefGoogle Scholar
  106. 106.
    Sexton DW, Al-Rabia M, Blaylock MG, Walsh GM (2004) Phagocytosis of apoptotic eosinophils but not neutrophils by bronchial epithelial cells. Clin Exp Allergy 34:1514–1524. doi: 10.1111/j.1365-2222.2004.02054.x PubMedCrossRefGoogle Scholar
  107. 107.
    Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A (2013) Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax 68:1157–1162. doi: 10.1136/thoraxjnl-2013-203204 PubMedCrossRefGoogle Scholar
  108. 108.
    Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM et al (2008) Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178:822–831. doi: 10.1164/rccm.200712-1894OC PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Bianchi SM, Prince LR, McPhillips K, Allen L, Marriott HM, Taylor GW et al (2008) Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med 177:35–43. doi: 10.1164/rccm.200612-1804OC PubMedCrossRefGoogle Scholar
  110. 110.
    McCaslin CA, Petrusca DN, Poirier C, Serban KA, Anderson GG, Petrache I (2015) Impact of alginate-producing Pseudomonas aeruginosa on alveolar macrophage apoptotic cell clearance. J Cyst Fibros 14:70–77. doi: 10.1016/j.jcf.2014.06.009 PubMedCrossRefGoogle Scholar
  111. 111.
    Vandivier RW, Richens TR, Horstmann SA, deCathelineau AM, Ghosh M, Reynolds SD et al (2009) Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. Am J Physiol Lung Cell Mol Physiol 297:L677–L686. doi: 10.1152/ajplung.00030.2009 PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Morimoto K, Janssen WJ, Terada M (2012) Defective efferocytosis by alveolar macrophages in IPF patients. Respir Med 106:1800–1803. doi: 10.1016/j.rmed.2012.08.020 PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP et al (2014) Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc 89:1130–1142. doi: 10.1016/j.mayocp.2014.03.016 PubMedCrossRefGoogle Scholar
  114. 114.
    Lee YJ, Moon C, Lee SH, Park HJ, Seoh JY, Cho MS et al (2012) Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction. Eur Respir J 40:424–435. doi: 10.1183/09031936.00096711 PubMedCrossRefGoogle Scholar
  115. 115.
    Amara A, Mercer J (2015) Viral apoptotic mimicry. Nat Rev Microbiol 13:461–469. doi: 10.1038/nrmicro3469 PubMedCrossRefGoogle Scholar
  116. 116.
    Moller-Tank S, Maury W (2014) Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. Virology 468–470:565–580. doi: 10.1016/j.virol.2014.09.009 PubMedCrossRefGoogle Scholar
  117. 117.
    Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S et al (2013) TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog 9, e1003232. doi: 10.1371/journal.ppat.1003232 PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E et al (2012) The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12:544–557. doi: 10.1016/j.chom.2012.08.009 PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Martin CJ, Peters KN, Behar SM (2014) Macrophages clean up: efferocytosis and microbial control. Curr Opin Microbiol 17:17–23. doi: 10.1016/j.mib.2013.10.007 PubMedCrossRefGoogle Scholar
  120. 120.
    Behar SM, Divangahi M, Remold HG (2010) Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 8:668–674. doi: 10.1038/nrmicro2387 PubMedPubMedCentralGoogle Scholar
  121. 121.
    Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, Keren I et al (2012) Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 12:289–300. doi: 10.1016/j.chom.2012.06.010 PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Dockrell DH, Lee M, Lynch DH, Read RC (2001) Immune-mediated phagocytosis and killing of Streptococcus pneumoniae are associated with direct and bystander macrophage apoptosis. J Infect Dis 184:713–722. doi: 10.1086/323084 PubMedCrossRefGoogle Scholar
  123. 123.
    Tzelepis F, Verway M, Daoud J, Gillard J, Hassani-Ardakani K, Dunn J et al (2015) Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. J Clin Invest 125:752–768. doi: 10.1172/JCI77014 PubMedCrossRefGoogle Scholar
  124. 124.
    Fujimoto I, Pan J, Takizawa T, Nakanishi Y (2000) Virus clearance through apoptosis-dependent phagocytosis of influenza A virus-infected cells by macrophages. J Virol 74:3399–3403PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Mares CA, Sharma J, Li Q, Rangel EL, Morris EG, Enriquez MI et al (2011) Defect in efferocytosis leads to alternative activation of macrophages in Francisella infections. Immunol Cell Biol 89:167–172. doi: 10.1038/icb.2010.81 PubMedCrossRefGoogle Scholar
  126. 126.
    Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH et al (2015) Glucocorticoid-augmented efferocytosis inhibits pulmonary pneumococcal clearance in mice by reducing alveolar macrophage bactericidal function. J Immunol 195:174–184. doi: 10.4049/jimmunol.1402217 PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Liu Y, Cousin JM, Hughes J, Van DJ, Seckl JR, Haslett C et al (1999) Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 162:3639–3646PubMedGoogle Scholar
  128. 128.
    McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C et al (2009) Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol 183:2167–2175. doi: 10.4049/jimmunol.0803503 PubMedCrossRefGoogle Scholar
  129. 129.
    Zizzo G, Hilliard BA, Monestier M, Cohen PL (2012) Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol 189:3508–3520. doi: 10.4049/jimmunol.1200662 PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    McCubbrey AL, Sonstein J, Ames TM, Freeman CM, Curtis JL (2012) Glucocorticoids relieve collectin-driven suppression of apoptotic cell uptake in murine alveolar macrophages through downregulation of SIRPalpha. J Immunol 189:112–119. doi: 10.4049/jimmunol.1200984 PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Yamaryo T, Oishi K, Yoshimine H, Tsuchihashi Y, Matsushima K, Nagatake T (2003) Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemother 47:48–53PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ et al (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689–698. doi: 10.1056/NEJMoa1104623 PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Asada K, Sasaki S, Suda T, Chida K, Nakamura H (2004) Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 169:195–200. doi: 10.1164/rccm.200207-740OC PubMedCrossRefGoogle Scholar
  134. 134.
    Lea S, Plumb J, Metcalfe H, Spicer D, Woodman P, Fox JC et al (2014) The effect of peroxisome proliferator-activated receptor-gamma ligands on in vitro and in vivo models of COPD. Eur Respir J 43:409–420. doi: 10.1183/09031936.00187812 PubMedCrossRefGoogle Scholar
  135. 135.
    Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP et al (2006) Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 176:7657–7665PubMedCrossRefGoogle Scholar
  136. 136.
    Soyseth V, Brekke PH, Smith P, Omland T (2007) Statin use is associated with reduced mortality in COPD. Eur Respir J 29:279–283. doi: 10.1183/09031936.00106406 PubMedCrossRefGoogle Scholar
  137. 137.
    Wang MT, Lo YW, Tsai CL, Chang LC, Malone DC, Chu CL et al (2013) Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 126:598–606. doi: 10.1016/j.amjmed.2013.01.036 PubMedCrossRefGoogle Scholar
  138. 138.
    Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R et al (2014) Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370:2201–2210. doi: 10.1056/NEJMoa1403086 PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Graham DK, DeRyckere D, Davies KD, Earp HS (2014) The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14:769–785. doi: 10.1038/nrc3847 PubMedCrossRefGoogle Scholar
  140. 140.
    Choi JY, Park HJ, Lee YJ, Byun J, Youn YS, Choi JH et al (2013) Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. J Pharmacol Exp Ther 344:447–458. doi: 10.1124/jpet.112.199778 PubMedCrossRefGoogle Scholar
  141. 141.
    Lee YJ, Han JY, Byun J, Park HJ, Park EM, Chong YH et al (2012) Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1/3, and NF-kappaB activation and enhances inflammatory responses in lipopolysaccharide-induced acute lung injury. J Leukoc Biol 91:921–932. doi: 10.1189/jlb.0611289 PubMedCrossRefGoogle Scholar
  142. 142.
    Meyer AS, Zweemer AJ, Lauffenburger DA (2015) The AXL receptor is a sensor of ligand spatial heterogeneity. Cell Syst 1:25–36. doi: 10.1016/j.cels.2015.06.002 PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM et al (2007) A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109:1026–1033. doi: 10.1182/blood-2006-05-021634 PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Ekman C, Linder A, Akesson P, Dahlback B (2010) Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care 14:R158. doi: 10.1186/cc9233 PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Wu J, Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Gottsater A et al (2011) Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther 13:R62. doi: 10.1186/ar3316 PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Manchester Collaborative Centre for Inflammation Research, Core Technology FacilityThe University of ManchesterManchesterUK

Personalised recommendations